Time is Brain oversubscribes a €3 million funding round and obtains CE/MDR approval to accelerate the adoption of Real-Time Stroke Intelligence in Europe
Home News Time is Brain oversubscribes a €3 million funding round and obtains CE/MDR approval to accelerate the adoption of Real-Time Stroke Intelligence in Europe

Time is Brain oversubscribes a €3 million funding round and obtains CE/MDR approval to accelerate the adoption of Real-Time Stroke Intelligence in Europe

JULY 15, 2026 Members' News

The funding and regulatory approval pave the way for European commercialization through strategic distribution partnerships.

Barcelona, Spain – July 9, 2026 – Time is Brain, a pioneer in the emerging category of Real-Time Stroke Intelligence, today announced two key milestones supporting its commercial expansion across Europe: the oversubscription of a €3 million Pre-Series A funding round and the CE/MDR approval of its flagship BraiN20® Real-Time Stroke Intelligence platform.

Together, these achievements represent a major step forward in the company’s mission to help clinicians make faster and better-informed stroke decisions through continuous neurological assessment and real-time clinical insights.

The funding will support commercial expansion, distributor onboarding, market access activities, and continued clinical evidence generation as Time is Brain prepares the European rollout of its platform later this year.

Stroke affects more than 10 million people worldwide every year and remains one of the leading causes of death and long-term disability. Every minute of delay in treatment increases the risk of irreversible brain damage. Although imaging technologies have transformed stroke diagnosis and treatment, many clinical decisions are still based on information captured at a single point in time.

Time is Brain was founded on the belief that clinicians need more than snapshot imaging—they need continuous neurological insights when every second counts.

"Stroke is one of the few medical emergencies where every minute directly impacts the patient’s future. Yet clinicians often make critical decisions using information captured at a single point in time," said Dr. Alicia Martínez, neurologist, co-founder and CEO of Time is Brain. "We believe the future of stroke care will combine imaging with continuous neurological intelligence, helping clinicians make faster and better-informed decisions when every second counts. CE/MDR approval and this investment enable us to bring that vision into clinical practice across Europe."

From snapshot imaging to Real-Time Stroke Intelligence

For decades, stroke care has relied on episodic assessment supported by imaging technologies such as CT and MRI. These tools remain essential for diagnosis, but they provide information captured at a single point in time.

Time is Brain believes the next evolution in stroke care is not about replacing imaging, but complementing it with continuous neurological assessment that provides specialists with real-time clinical insights throughout the entire patient journey.

This shift represents the transition from snapshot imaging to Real-Time Stroke Intelligence, enabling healthcare professionals to make faster and better-informed decisions during pre-hospital triage, emergency department assessment, and in-hospital treatment.

Creating a new category

Time is Brain is creating a new category: Real-Time Stroke Intelligence.

By transforming brain activity into actionable clinical insights, the company’s platform enables clinicians to continuously assess neurological function throughout the entire stroke care pathway. Through continuous neurological assessment and AI-powered neuro-monitoring, clinicians gain additional insights to support faster and better-informed treatment decisions when time is critical.

Real-Time Stroke Intelligence complements the current imaging-based standard of care by providing continuous neurological assessment that supports clinical decision-making throughout the stroke journey.

The company’s first commercial platform, BraiN20®, has been developed to integrate seamlessly into existing stroke workflows while complementing established imaging techniques. The platform supports clinicians in three critical stages of care:

  • Pre-hospital stroke triage
  • Emergency department assessment
  • In-hospital treatment and monitoring

"Imaging remains fundamental in stroke care, but it only provides part of the clinical picture," said Dr. Antoni Dávalos, co-founder and Chief Scientific Officer of Time is Brain. "Continuous assessment of brain function provides complementary insights that can support therapeutic decisions throughout the patient journey. This is the clinical foundation of Real-Time Stroke Intelligence."

Expansion across Europe

Following CE/MDR approval, Time is Brain is preparing the commercial launch of BraiN20® across Europe starting later this year.

To support this commercial expansion, the company has built a global network of more than 50 stroke key opinion leaders (KOLs) and clinical champions. It also continues to collaborate with healthcare professionals worldwide who are ready to become early adopters and help redefine the future of stroke diagnosis and prognosis.

Time is Brain is seeking partners with established relationships in stroke care, emergency medicine, and neurology who share its vision of advancing Real-Time Stroke Intelligence and introducing this new approach to stroke assessment across three key clinical settings:

  • Pre-hospital stroke triage
  • Emergency department assessment
  • In-hospital treatment and monitoring

Hospitals, healthcare providers, stroke networks, and distributors interested in collaborating with Time is Brain are invited to contact the company to explore partnership opportunities.

As healthcare systems increasingly seek solutions that improve clinical decision-making and reduce treatment delays, Time is Brain believes that Real-Time Stroke Intelligence will become an essential complement to modern stroke care.

About Time is Brain

Time is Brain is a pioneer in the emerging category of Real-Time Stroke Intelligence.

The company’s platform delivers AI-powered continuous neuro-monitoring that transforms brain activity into actionable clinical insights, helping clinicians make faster and better-informed stroke decisions throughout the entire patient journey.

By enabling continuous assessment of brain function when every second counts, Time is Brain is helping shape the future of stroke care through intelligent clinical decision support.

November 20, 2026 Members' News
Derm2check Breaks Away From One-Sided AI Skin Apps
Dutch platform combines a free AI skin check with an international network of dermatologists, from first suspicion to treatment Derm2check is the result of a pilot phase of about a year, during which broad experience was built up worldwide in digital dermatological care. That practical experience has now been incorporated into a fully renewed platform, which combines AI technology with a free AI Check for users.
Read more
November 20, 2026 Members' News
SMED Clinical Research joins the Barcelona & Madrid Health Hub
Joining Barcelona & Madrid Health Hub marks an important step for SMED Clinical Research as the company continues to strengthen its presence within the healthcare and life sciences ecosystem. It creates new opportunities to stay close to innovation, collaborate with leading organisations, and better understand the evolving needs of sponsors, clinical sites and the patients they serve.
Read more
November 19, 2026 Members' News
Partner Insights 2026: Technology, Innovation and Collaboration in Life Sciences
Ambit Iberia has launched Partner Insights 2026, the new edition of its annual magazine bringing together the perspectives of 13 technology partners on the trends, challenges and opportunities shaping the future of the Life Sciences industry.
Read more
November 19, 2026 Members' News
Artificial Intelligence comes to informed consent to answer patients’ questions before surgery
Informed consent is a routine process in any hospital, but its management continues to generate costs, administrative workload and traceability issues when carried out on paper. To address these challenges, ASHO has developed a new end-to-end informed consent management platform that digitizes the entire process and gives patients a more active role, allowing them to access the information in advance, resolve their questions before signing and arrive at surgery with a better understanding of the procedure.
Read more
November 18, 2026 Members' News
Corporate Nutrition for Every Type of Work. The Great Blind Spot in Workplace Wellness
Do we really take care of all the factors that influence team well-being? In recent years, companies have made progress in mental health, work-life balance, flexibility, and creating healthier work environments. However, there is one element that often remains outside the strategy or is treated in a merely informative way: nutrition during the workday.
Read more
November 16, 2026 Members' News
M2H brings exercise prescription into Primary Care: doctors and exercise specialists, finally on a single digital layer
The Barcelona-based healthtech startup, a new member of Barcelona & Madrid Health Hub, connects family doctors and Physical Exercise Specialists within the same clinical workflow, keeping full patient traceability.
Read more
November 13, 2026 Members' News
Fund It, Build It, Certify It: A MedTech Startup's Roadmap to Market
Most MedTech startups don't stall because the technology fails. They stall because funding and regulation were planned separately. Under MDR, compliance is not the last step before submission. It shapes your product and company decisions from day one. And investors know it: before a Series A or B, they expect a credible regulatory strategy, not just a promising prototype. That's why, QbD Group and Capital Cell teamed up, to bring both sides together in one free webinar live session.
Read more
November 13, 2026 Members' News
The Ultimate Guide for Choosing an Enterprise CMS
In strictly regulated industries like pharmaceutical and health insurance, delivering seamless, compliant digital experiences—from patient portals to provider resources—is critical. Magnolia is a leading composable Digital Experience Platform (DXP) trusted by healthcare and global enterprise giants like Sanofi and Generali. By centralizing websites, portals, and apps into one intuitive, open platform, Magnolia's CMS empowers IT teams to build freely and marketing teams to launch faster—all while protecting brand integrity and compliance.
Read more
November 12, 2026 Members' News
Health Tech Enterprise launches half-price UK market entry offer for Barcelona & Madrid Health Hub members
Health Tech Enterprise introduces an exclusive UK Market Entry Pathfinder offer for Barcelona & Madrid Health Hub members, helping MedTech companies assess their readiness for UK expansion and receive an evidence-based market entry recommendation within 21 days, with preferential member pricing available until 31 December 2026.
Read more
November 12, 2026 Members' News
Your Next Innovation May Already Exist
Connecting business challenges with scientific knowledge
Read more